The Effect of Amantadine on Post-COVD-19 Fatigue

Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Dec 26, 2022

Keywords

ClinConnect Summary

Background The 2019 coronavirus disease has severely affected the health of the general public. Even after recovery, this disease can cause problems, including chronic fatigue, which the patient can suffer from for years and cause permanent disability for a number of patients.

Despite the fact that fatigue due to COVID-19 has affected many patients, not many studies have been done in the field of effective treatment for this problem.

In this study, the investigators studied the effect of amantadine on the fatigue of COVID-19 patients.

Method In this clinical trial study, 83 patients were...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • clinical diagnosis of COVID-19
• • clinical evidence of fatigue despite the passage of 30 to 60 days from the onset --of the symptoms of COVID-19
• • willingness and informed consent to participate in the study
• Exclusion Criteria:
• • the recurrence of COVID-19 in the form of re-infection
• • history of psychiatric diseases
• • psychotic disorders (in the form of hallucinations and delusions)
• • anxiety disorders and major depression
• • substance abuse in the last four months
• • taking antidepressants during the last six weeks
• • corticosteroids consumption during the last six weeks
• • taking psychostimulant drugs
• • an unstable medical condition
• • cognitive disorders and confusion
• • withdrawal from participating in the study
• • history of rheumatological disease
• • getting cancer and malignancy
• • advanced chronic diseases (heart, liver, kidney, etc.)
• • edema of organs
• • hypertension (untreated)
• • hypogonadism (untreated)
• • hypothyroidism (untreated)
• • anemia (untreated)
• • pregnancy and breastfeeding
• • nausea and vomiting when starting to take Amantadine
• • convulsions
• • dyspnea
• • post-COVID-19 encephalopathy